Better Coronavirus Stock: Moderna or Pfizer?
As 2020 draws to a close, all eyes are peeled on Pfizer (NYSE: PFE) and Moderna (NASDAQ: MRNA). The two companies have been working throughout the year to create vaccines against the novel coronavirus that has taken nearly 1.6 million lives globally.
On Dec. 11, Pfizer received an Emergency Use Authorization (EUA) from the U.S. Food and Drug Administration (FDA). Pfizer's coronavirus candidate, BNT162b2, is based on messenger RNA (mRNA) technology and was developed with its German biotech partner BioNTech (NASDAQ: BNTX). The candidate displayed 95% efficacy in the still-ongoing phase 3 trial.
Meanwhile, Moderna's mRNA vaccine candidate, mRNA-1273, reported an efficacy rate of 94.1%. Moderna received a EUA on Dec. 18, just one day after the agency's advisory committee unanimously recommended authorizing the vaccine.
Source Fool.com
